A homologous protein also carrying the acyl-CoA binding domain, ACBD3, was highly expressed in primary pigmented nodular adrenocortical disease (PPNAD) tissues (Liu, Li & Papadopoulos, 2003), lung cancer tissue in treated patients that did not respond to gefitinib (Kakiuchi et al., 2004), colonic mucosa cancer tissue upon pretreatment versus post-treatment with celecoxib (Glebov et al., 2006), and bone tissue in osteosarcoma patients (Jones et al., 2012), supporting a role as a potential oncogene (Fan et al., 2010). Here, ACBD3 is linked to osteosarcoma.